Sector News

NICE recommends Novo Nordisk treatment for adults with obesity

November 6, 2020
Life sciences

National Institute for Health and Care Excellence (NICE) has recommended a new treatment option developed by Novo Nordisk for adults with obesity and non-diabetic hyperglycaemia.

NICE recommends Saxenda (Liraglutide) alongside a reduced-calorie diet and increased physical activity.

The pre-filled injection pens will be available to adults with a body mass index (BMI) of at least 35 kg/m2 and a high risk of cardiovascular disease resulting from high blood pressure or cholesterol levels.

A specialist multidisciplinary tier 3 weight management service will prescribe Saxenda in secondary care.

Those referred to a tier 3 service will first receive weight management interventions in a local, intensive lifestyle-change programme such as the NHS diabetes prevention programme.

To receive the treatment, all recommended eligibility criteria must be met.

With the treatment duration being two years, the therapy should be discontinued if at least 5% reduction in body weight is not achieved after 12 weeks on the full dose.

NICE Centre for Health Technology Evaluation deputy chief executive and director Meindert Boysen said: “Our independent committee was presented with clinical evidence which showed that people lose more weight with liraglutide plus lifestyle measures than with lifestyle measures alone.

“Liraglutide may also delay the development of type 2 diabetes and cardiovascular disease and this is the main benefit of treatment.”

Earlier, NICE was unable to recommend this treatment as the cost-effectiveness estimate was higher when compared to other NHS resources.

But lately, Novo Nordisk agreed on a confidential discount with NHS England and NHS Improvement that allows for its recommendation.

by pharmaceutical-technology.com

Source: pharmaceutical-technology.com

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend